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Abstract
The aim of the present study was to compare the effects of Daivobet® and calcipotriol on clinical
score and biomarker responses in a modified version of the Scholtz-Dumas psoriasis plaque assay.
Furthermore, it was the aim to compare the effects of calcipotriol and betamethasone in the
murine psoriasis xenograft model. Twenty four patients with psoriasis were treated topically once
daily for three weeks, whereas the grafted mice were treated for four weeks. Clinical responses
were scored twice weekly and biopsies were taken at the end of each study to analyse for skin
biomarkers by histology and immunohistochemistry. The results clearly demonstrate effects on
both clinical signs and biomarkers. In the patient study the total clinical score was reduced
significantly with both Daivobet® and calcipotriol. Both treatments reduced epidermal thickness,
Ki-67 and cytokeratin 16 expression. T cell infiltration was significantly reduced by Daivobet® but
only marginally by calcipotriol. Both treatments showed strong effects on the epidermal psoriatic
phenotype.
Results from the xenograft model essentially showed the same results. However differences were
observed when investigating subtypes of T cells.
The study demonstrates the feasibility of obtaining robust biomarker data in the psoriasis plaque
test that correlate well with those obtained in other clinical studies. Furthermore, the biomarker
data from the plaque test correlate with biopsy data from the grafted mice.
Background
Psoriasis is a common skin disease characterized by
increased inflammation as well as increased proliferation
and altered differentiation of keratinocytes, resulting in
characteristic plaques on the skin [1]. The complexity of
this disease and the fact that the structure of human skin
is very different from most animals has made it very chal-
lenging to mimic human psoriasis in preclinical models.
In the search for new effective topical treatments of psoria-
sis it is therefore important to be able to get early clinical
"proof-of-concept" in psoriasis patients as well as an
understanding of the mechanism of action as early as pos-
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sible. This also enables early discontinuation of the devel-
opment of non-effective compounds. One possibility is
the use of experimental clinical models such as the psoria-
sis plaque test, originally developed by Scholtz and
Dumas [2], which allows simultaneous topical treatment
with several active compounds and controls in the same
psoriasis patient. The psoriasis xenograft SCID mouse
model is probably the most relevant animal model for
efficacy testing of novel anti-psoriatic drugs [3]. In this
model, keratome biopsies from psoriatic plaques are
transferred to the back of SCID mice and the mice are sub-
sequently treated with compounds either systemically or
topically. The model has been used for several years and is
recognized as predictive for the outcome in clinical trials.
However, it is still debated which endpoints are relevant
and to what extent the investigation of biomarkers in this
model is meaningful.
In the present study we compare the effects of ointment
vehicle, calcipotriol ointment and calcipotriol plus beta-
methasone dipropionate (BDP) ointment (Daivobet®) on
the clinical score in a psoriasis plaque test as well as the
effect on skin biomarkers, both in the clinical setting and
the preclinical psoriasis model.
Materials and methods
Patients and design
Twenty-four patients with stable chronic plaque-type pso-
riasis were included in this study after the relevant Inde-
pendent Ethic Committee gave its approval and the
patients gave their signed informed consents. The clinical
investigation was conducted according to Declaration of
Helsinki principles and Good Clinical Practice. The study
was a single centre, investigator blinded, within-subject
randomised, active- and vehicle-controlled, repeated dose
study, conducted at CPCAD, Nice, France. No topical
treatment had been applied for four weeks prior to admis-
sion and none of the patients had received systemic treat-
ment for their psoriasis within 12 weeks prior to the study.
The study was conducted as a modified version of the pso-
riasis plaque test derived from the method described by KJ
Dumas and JR Scholtz [2]. For each subject, six test sites of
2-cm diameter were selected on predetermined lesions,
and a circular adhesive device was placed on each site. The
study medications were applied six times a week (once
daily Monday to Saturday) for three weeks, using an
Eppendorf®  combitip and they were rubbed into the
lesions using a gloved finger. The test sites were then cov-
ered with an unocclusive gaze and the system was secured
on the skin using a Tegaderm®  (3 M, Cergy-Pontoise
Cedex, France) dressing with a hole at the centre. The test
areas were randomised and treated with Daivobet® oint-
ment (calcipotriol 50 μg/g plus betamethasone 0.5 mg/g
as diprosone), calcipotriol ointment (50 μg/g), three
experimental formulations and ointment vehicle.
Clinical rating was performed twice a week during the
treatment phase assessing the Total Clinical Score (TCS).
The Total Clinical Score is defined as the sum of erythema
(0-3), scaling (0-3) and thickness (0-3) scores. Total Clin-
ical Scores therefore range from 0 (all symptoms absent)
to 9 (all symptoms severe).
At the end of the treatment (on the day after the last treat-
ment) all subjects had two 4 mm punch biopsies taken
from two of the three sites treated with Daivobet® oint-
ment, the calcipotriol ointment and ointment vehicle. A
biopsy randomisation was put in place to ensure that an
equal amount of biopsies was taken from each of these
three treatments. The biopsies were fixed in buffered for-
malin immediately after sampling and fixed for at least 24
hrs before being embedded in paraffin.
Sampling of biopsies for the psoriasis xenograft SCID 
mouse model
Patients suffering from chronic plaque-psoriasis were
used as donors for the psoriatic keratome biopsies. The
removal of skin and subsequent experiments were
approved by the local ethical committees and the patients
gave their signed informed consent. Patients were locally
anesthetized and psoriatic keratome biopsies (thickness
0.5 mm) were removed using a dermatome shaver. Three
keratome biopsies (containing both dermis and epider-
mis) were obtained after informed consent from four pso-
riasis patients. Biopsies were taken from infiltrated red
plaques located on the anterior or lateral aspect of the
femoral region.
Grafting of mice
The keratome biopsy from each patient was divided into
pieces of 1.5 × 1.5 cm. As recipients, female CB.17 SCID
mice (M&B Taconic, Denmark) aged 6 weeks were used.
The mice were anesthetized using a mixture of Ketamin
(Ketaminol Vet, Intervet, Denmark) and Xylazin
(Rompun Vet, Bayer A/S, Denmark) and a fully excision
biopsy was removed from the back of the animals. The
split human keratome biopsies were then grafted onto the
back of the animals. The grafts were protected by a band-
age during the following two weeks. All the transplanta-
tion procedures were performed under semi-sterile
conditions. The animals were stored in special-pathogen-
free (SPF) environment during entire experiment. The
experiments were carried out in accordance with the local
ethics committee and with animal welfare guidelines pro-
vided by the Animal Experiments Inspectorate, Ministry of
Justice, Denmark.
Treatment of animals
After two weeks of rest, the animals were randomized into
three groups. The groups were treated with the calcipotriol
ointment (calcipotriol, 50 μg/g) (n = 7), betamethasoneJournal of Translational Medicine 2009, 7:107 http://www.translational-medicine.com/content/7/1/107
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(0.5 mg/g (as diproprionate; BDP) in ointment (n = 4) or
ointment vehicle (n = 5) twice daily.
After 4 weeks of treatment, the animals were bled and sac-
rificed, and a 4-mm punch biopsy was taken from each
xenograft. Biopsies were fixed in 10% neutral buffered for-
malin for a maximum of 48 hours, were processed accord-
ing to standard histological procedures and embedded in
paraffin. Tissue sections were mounted on adhesive slides
(Superfrost®  Plus, MENZEL-GLASER, Germany) and
stained with hematoxylin and eosin (H&E, Merck, Darm-
stadt, Germany). Immunohistochemical stainings were
performed as described under Immunohistochemistry.
Immunohistochemistry
The following markers were investigated: (i) T cell infiltra-
tion: CD3, CD4, CD8, CD45RO; (ii) epidermal differenti-
ation: fraction of cytokeratin 10 (CK10) and cytokeratin
16 (CK16) positive epidermis (iii); epidermal prolifera-
tion: Ki-67-positive keratinocytes.
The tissue blocks were sectioned into 3-4 μm sections,
mounted on adhesive slides (Superfrost® Plus, MENZEL-
GLÄSER, Germany) and kept at 4°C until processed.
Prior to staining the tissue sections were deparaffinized
and rehydrated and then incubated in hydrogen peroxide
(3%) for 5 min to quench endogenous peroxidase (opti-
mal immunohistochemical staining of CD4 required
blocking of endogenous HRP after incubation of the pri-
mary antibody).
Sections were then submitted to heat induced epitope
retrieval by incubation in boiling Tris-EGTA (T-EG) buffer
(pH 9) in a microwave oven for 15 min. This was followed
by incubation in the T-EG buffer for 15 min at room tem-
perature (RT), and afterwards by 5 min incubation in TBS/
Tween (LAB42006, Bie & Berntsen, Rødovre, Denmark).
All subsequent incubations were performed on a DAKO
Autostainer (Dako Autostainer Plus, DAKO, Glostrup,
Denmark) at RT. The slides were mounted into the auto-
stainer and washed in Wash Buffer (S3006), after which
unspecific protein binding was blocked by incubation in
10% goat serum (X0907, DAKO, Glostrup, Denmark) for
10 min. All slides were incubated with primary antibody
diluted in Antibody Diluent (S2022, DAKO, Glostrup,
Denmark) at different concentrations for 1 h. The follow-
ing primary antibodies were used: anti-CD3 (polyclonal;
2 mg/L), anti-CD8 (clone C8/144B, 2 mg/L), anti-
CD45RO (clone UCHL1; 4,4 mg/L), anti-CK10 (clone
DE-CK10, 1 mg/L), anti-Ki-67 (clone MIB-1, 0,5 mg/L),
all obtained from DAKO, Glostrup, Denmark, anti-CK16
(clone LL025, 2,5 mg/L) obtained from AbD Serotec,
Scandinavia and anti-CD4 (clone 1F6, 2 mg/L) obtained
from NovoCastra, UK.
The detection systems EnVision+ for rabbit antibodies
(K4003, DAKO, Glostrup, Denmark) and EnVision for
mouse antibodies (K4001, DAKO, Glostrup, Denmark)
were applied according to the manufacturers' instructions.
Slides were stained with liquid diaminobenzidine tetrahy-
drochloride (DAB+), a high-sensitivity substrate-chro-
mogen system (K3468, DAKO, Glostrup, Denmark).
Counterstaining was performed with Meyer's haematoxy-
lin. The sections were washed in tap and distilled water
and mounted with Pertex. Control immunohistochemical
stainings were run on parallel sections without the pri-
mary antibody and with a nonsense polyclonal or mono-
clonal (matching isotype) antibody at same concentration
as the primary antibody.
Immunohistochemical evaluation
The immunohistochemical stainings were assessed on an
Olympus BX51 light microscope coupled to a computer
equipped with Microimager software. All positive cells in
one representative and blinded tissue section were
counted.
In the evaluation of staining for CD3, CD4, CD8,
CD45RO, only cells with staining restricted to the plasma
membrane and a visible nucleus were counted as positive.
Cells in the epidermis and the 200 μm of dermis below
the basement membrane were counted with a 20× objec-
tive and the numbers were reported per mm2. In the eval-
uation of staining for Ki67, only epidermal cells with
nuclear staining were counted as positive and reported as
No/mm (surface length). The distribution of CK10 and
CK16 in epidermis was measured by absolute numbers
using the fraction of the positively stained epidermal area,
i.e. the area of positive CK10 or CK16 in relation to the
total epidermal area. These measurements were per-
formed with the Visiopharm Integrator System software
(VIS, Visiopharm, Hørsholm, Denmark) on serial sec-
tions.
Histopathological evaluation
Haematoxylin and eosin (HE) stained sections from the
plaque test study were evaluated by a pathologist in a
blinded fashion. The following parameters were meas-
ured in absolute numbers or scored semi-quantitatively
using a 0-3 scale: Epidermal thickness, thinning (absence)
of stratum corneum, extent of stratum granulosum, extent
of parakeratosis, extent of inflammatory cell infiltration
and frequency of neutrophil microabscesses.
Statistics
Clinical data: Since the effects of three treatments were
analysed based on only two biopsies per patient the statis-
tical analysis was based on data in an incomplete block
structure. The study and statistical design was chosen so as
to make the data as balanced as possible. P-values wereJournal of Translational Medicine 2009, 7:107 http://www.translational-medicine.com/content/7/1/107
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calculated with standard assumptions about independ-
ence, equivariance and normality. Due to heteroscedacity,
the logarithm of the following response variables was
used: CD3, CD4, CD45, and Ki-67. SCID mouse data: Data
from the SCID mice were analysed with a two-sample t-
test with Welch-Satterthwaite approximation for the
degrees of freedom. All P-values were computed using the
R package (R Development Core Team, 2008).
Results
Patient study
The clinical and biomarker scores are shown in Figure 1
and Table 1, respectively, and the correlation between
total clinical score (TCS) and biomarkers is shown in Fig-
ure 2. The mean reductions in TCS between day 0 and day
21 was 2.71 (44%), 4.48 (73%) and 6.19 (100%) for the
ointment vehicle, calcipotriol ointment and Daivobet®
ointment groups, respectively. The reduction induced by
calcipotriol was statistical significant (p < 0.001) com-
pared to vehicle at day 21. Daivobet® reduced TCS signifi-
cantly compared to both vehicle (p < 0.001) and
calcipotriol (p < 0.001). The reduction was statistical sig-
nificant (p < 0.05) from day 4 for Daivobet® and at day 11
for calcipotriol.
Daivobet® induced a highly significant reduction in epi-
dermal thickness compared to vehicle (72%) and an
almost complete normalisation of the epithelial morphol-
ogy (Table 1 and Figure 3). Stratum granulosum was nor-
malized and parakeratosis was absent in all samples
treated with Daivobet®. This was supported by the lack of
CK16 staining in these samples. Furthermore, the number
of Ki-67 positive epidermal cells was reduced by 83%
compared to vehicle treated skin. The correlation of epi-
dermal thickness, proliferative activity (Ki-67 expression)
and cytokeratin 16 expression with TCS is shown in Figure
2. Treatment with Daivobet® also induced a highly signif-
icant reduction in CD3, CD4, CD8 and CD45RO positive
T cells (Table 1).
Treatment with calcipotriol for three weeks reduced the
epidermal thickness significantly (22%) compared to the
vehicle treated group. The epidermal morphological
parameters (extent of stratum corneum, stratum granulo-
sum and parakeratosis) were also significantly influenced
by calcipotriol treatment (Table 1). Although both the
number of proliferating Ki-67 positive cells and the frac-
tion of CK16 positive epithelium were reduced compared
to vehicle (36% and 47%, respectively) these numbers did
not reach statistical significance (Table 1). In addition,
none of the T-lymphocyte subsets (CD3, CD4, CD8 and
CD45RO) was significantly influenced by calcipotriol
treatment (Table 1 and Figure 3).
Interestingly, neither calcipotriol nor Daivobet® treatment
induced any change in the fraction of CK10 expression
epithelium.
Psoriasis xenograft SCID mouse model
At study end the mean epidermal thickness for the vehicle
(n = 6) treated animals was 344 ± 123 μm, 236 ± 47 μm
for calcipotriol (n = 7) treated animals (31% reduced epi-
dermal thickness compared with the vehicle group) and
94 ± 49 μm for betamethasone diproprionate (BDP) (n =
4) treated animals (73% reduced epidermal thickness
compared with vehicle group) (Table 2). This reduction
only reached statistical significance for BDP when com-
pared to the vehicle group. The effect on the biomarkers
showed the same trends as observed in the patient study
(Table 2). A comparison of the keratome biopsies before
and after transplantation showed that the number of CD3
seemed to increase and the expression of CD4 and CD8
Table 1: Immunohistochemical and histopathological scores obtained from skin biopsies from the psoriasis plaque test with 
treatments of vehicle, calcipotriol and Daivobet® ointment.
Vehicle calcipotriol Daivobet®
n = 16 n = 16 p-value vs.
vehicle
n = 16 p-value vs.
vehicle
p-value vs.
calcipotriol
CD3 (number/mm2) 351.7 ± 261.0 309.0 ± 199.0 NS 97.6 ± 72.5 <0.001 <0.001
CD4 (number/mm2) 347.9 ± 221.7 289.2 ± 128.9 NS 104.2 ± 69.1 0.001 0.002
CD8 (number/mm2) 156.0 ± 111.7 152.4 ± 113.3 NS 44.5 ± 30.2 <0.001 <0.001
CD45RO (number/mm2) 419.0 ± 284.4 329.9 ± 201.7 NS 96.1 ± 70.4 <0.001 <0.001
Ki-67 (number/mm) 258.5 ± 140.5 165.8 ± 107.5 NS 43.2 ± 25.7 <0.001 <0.001
CK10 (% area) 64.2 ± 9.3 65.5 ± 10.7 NS 68.8 ± 13.3 NS NS
CK16 (% area) 21.4 ± 22.5 11.4 ± 15.7 NS 0.1 ± 0.4 <0.001 0.028
Epidermal thickness (μm) 191.0 ± 67.6 148.8 ± 63.4 0.01 66.5 ± 15.3 <0.001 <0.001
Strat corneum (extent) 2.1 ± 1.0 1.0 ± 0.8 0.002 0.2 ± 0.4 <0.001 0.005
Strat granulosum (extent) 1.4 ± 1.4 0.4 ± 0.9 0.007 0.0 ± 0.0 <0.001 NS
Parakeratosis (extent) 1.6 ± 1.3 0.5 ± 0.9 0.002 0.0 ± 0.0 <0.001 0.04
Infiltration (extent) 1.5 ± 0.6 1.2 ± 0.4 NS 0.9 ± 0.3 <0.001 NS
NS, not significant.Journal of Translational Medicine 2009, 7:107 http://www.translational-medicine.com/content/7/1/107
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decreased (Figure 4). The dose of calcipotriol and BDP
was well tolerated and no significant weight loss was
observed. Two hours after the last application, the ani-
mals were bled and sacrificed. The serum levels of calcipo-
triol and BDP were analyzed and determined to be below
the detection limit (data not shown).
Discussion
The objective of this study was to assess the clinical and
biomarker responses of psoriasis patients treated with
topical anti-psoriatic compounds in a plaque test study
and to compare these data with those obtained in larger
clinical studies. Furthermore, we wanted to use the
biomarker data to compare biological effects in patients
and the psoriasis xenograft mouse model.
In this psoriasis plaque test study of Daivobet® ointment
and the calcipotriol ointment we observed a significant
clinical effect of both treatments compared to vehicle
treated skin. After three weeks of treatment the TCS was
reduced by 84% and 61% by Daivobet® and calcipotriol
ointment, respectively. These clinical effects of Daivobet®
and calcipotriol ointment are in good agreement with pre-
viously published data from larger clinical studies [4-6].
The time course of the clinical effects also matched those
seen in other clinical studies, with a fast onset by Daivo-
bet® already showing significant clinical effect at day 4. As
in other topical psoriasis studies a significant vehicle effect
was observed, with a reduction of 37% in the total clinical
score over three weeks by the ointment vehicle alone [7].
In this study a treatment arm with betamethasone dipro-
prionate ointment alone was not included as the effects of
betamethasone and Daivobet has been compared in
another plaque test study. Using our standardised proce-
dures these studies correlate well with regard to clinical
effect. Epidermal thickness, proliferative activity (Ki-67
expression) and cytokeratin 16 expression are generally
considered good markers of psoriasis activity [8,9]. In this
study, these parameters also correlated well with the clin-
ical score in the vehicle group (Figure 2).
Furthermore, a number of morphological parameters,
such as the degree of parakeratosis, stratum corneum and
stratum granulosum, are profoundly altered in psoriasis
compared to normal skin. In this study the morphological
changes correlated well with the clinical score and the
psoriatic phenotype was strongly reduced by both the cal-
cipotriol ointment and Daivobet® (Table 1).
The effectiveness of calcipotriol in the treatment of psoria-
sis has primarily been attributed to its effects on epider-
mal proliferation and differentiation/keratinisation [10-
12] although the effects on skin infiltrating T cells are rel-
evant to its mode of action [13,14]. Calcipotriol has been
shown to reduce CD3, CD4, CD8 and CD45RO positive
T-cells in psoriatic skin [15].
There was a clear trend towards reduction of Ki-67, CK16
and T cell infiltration by the calcipotriol ointment in this
study compared to the vehicle group, although, this
reduction did not reach statistical significance (Table 1).
The biopsies in this study were taken on day 22 and the
biomarkers were therefore only scored at the end of the
study. Considering the marked vehicle effect of the oint-
ment vehicle observed on clinical score, it is likely that the
biomarkers are also strongly affected by the vehicle treat-
ment. This is supported by the finding that the patients
with most pronounced vehicle effect on clinical score had
normalised their biomarker profile (epidermal morphol-
ogy, epidermal thickness, CK16 and Ki-67 expression) in
the vehicle treated area (data not shown).
In other studies the calcipotriol ointment has shown sig-
nificant reduction in biomarkers of epidermal prolifera-
tion, differentiation and lymphocyte infiltration [15-17].
However, these studies compared the biomarker profiles
before and after treatment with the calcipotriol ointment
and they did not assess the effects of the vehicle on the
biomarker responses. Ointment vehicles, as used in these
studies, are known to have a significant effect on the clin-
ical score in psoriasis and most likely also on the biomar-
kers.
Cytokeratin 10 is a marker of normal epidermal differen-
tiation and previous studies have shown an increase in the
keratinocyte population expressing CK10 after treatment
with calcipotriol when comparing to the pre-treatment
levels [14,15,17]. In this study, we were not able to dem-
onstrate an effect of Daivobet® or calcipotriol ointment on
cytokeratin 10 expression compared to vehicle. This is
Percent reduction (mean ± SEM, n = 12) in total clinical  score (TCS) from day 1 to day 22 after treatment with  Daivobet® vehicle, calcipotriol and Daivobet® once daily 6  times weekly (excl. Sunday) for three weeks Figure 1
Percent reduction (mean ± SEM, n = 12) in total clin-
ical score (TCS) from day 1 to day 22 after treatment 
with Daivobet® vehicle, calcipotriol and Daivobet® 
once daily 6 times weekly (excl. Sunday) for three 
weeks.
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most likely due to the high vehicle effect and the lack of
baseline data.
The psoriasis xenograft SCID mouse model is currently
one of the most accepted and well characterized animal
model for screening of novel anti-psoriatic compounds
[3,18]. In the present study, lesional psoriatic skin was
removed from volunteer donors suffering from chronic
plaque psoriasis and grafted onto the back of immune
deficient SCID mice. It has been debated which parame-
ters could be used as endpoints in this model. Histological
parameters such acanthosis and hyperkeratosis are gener-
ally accepted to be maintained during the study. However,
it is controversial to what extent immunological parame-
ters such as changes in T cell populations can be used [19].
To evaluate the effect of the calcipotriol ointment and
BDP in this model, we tested the compounds topically
and compared the results to the findings from the plaque
test. The effect on the biomarkers showed the same trends
as observed in the plaque test study. The epidermal thick-
ness was significantly reduced following treatment with
both the calcipotriol ointment and steroid and a clear
trend in the reduction of the number of CD3, CD4, CD8
and CD45R0 positive cells was observed following treat-
ment with steroid but not following treatment with the
calcipotriol ointment. Statistically significant differences
between the effects of the treatments were not seen on the
biomarkers due to low number of animals in the in vivo
study. We also observed a reduction of CK16 and Ki67 fol-
lowing both treatments. This indicates that the model is
valid in regard to many parameters when evaluating the
effect of antipsoriatic drugs topically. However, a general
reduction of all cellular markers was observed in the grafts
following the study in all groups. Furthermore, the total
number of CD4 or CD8 positive cells was 10 - 30% of the
number of CD3 positive cells. Since this was not observed
to the same extent in the patient study, it indicates that
CD4 and CD8 are heavily down regulated during the
study. The loss of CD4 and CD8 receptors may be a con-
Correlation between biomarker responses and total clinical score in skin samples from psoriasis patients treated for three  weeks with ointment vehicle Figure 2
Correlation between biomarker responses and total clinical score in skin samples from psoriasis patients 
treated for three weeks with ointment vehicle. Correlation of clinical score with epidermal thickness (A; r = 0.733), 
CD3 positive T cells (B; r = 0.375), Ki-67 positive cells (C; r = 0.675) or cytokeratin 16 positive cells (D; r = 0.628).
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Biomarker endpoints after treatment with vehicle (A, D, G and J), calcipotriol (B, E, H and K) and Daivobet® (C, F, I and L) in  the psoriasis plaque assay Figure 3
Biomarker endpoints after treatment with vehicle (A, D, G and J), calcipotriol (B, E, H and K) and Daivobet® 
(C, F, I and L) in the psoriasis plaque assay. A-C: Masson-Trichrome (MT) staining showing epidermal hyperplasia. D-F: 
Proliferation of keratinocytes in stratum basale of epidermis (Ki-67). G-I: Immunohistochemical staining with a pan-T cell 
marker (CD3). J-L: Epidermal expression of keratin 16 show decrease after treatment with calcipotriol and is absent after 
treatment with Daivobet®.
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sequence of extensive activation and exhaustion among
the T cells in the graft (Figure 4). Even though CD4 posi-
tive cells can be depleted effectively in the model [20], this
indicates that the immune cells in the grafts undergo
severe phenotypic changes during the study. Thus, conclu-
sions in regard to investigations of cellular biomarkers
should be treated with caution as they could be mislead-
ing when investigated in the psoriasis xenograft SCID
mouse model. In spite of these shortcomings, the
xenograft mouse model is a useful preclinical psoriasis
model that provides important information on the bio-
logical effect of anti-psoriatic treatments. On the other
hand, the plaque test model clearly provides much more
relevant data. This study has demonstrated that both clin-
ical and biomarker results obtained from the psoriasis
plaque test are in line with regular clinical studies. It is
Table 2: Immunohistochemical scores obtained from skin biopsies from xenografted SCID mice treated with vehicle, calcipotriol and 
betamethasone dipropionate (BDP).
Vehicle calcipotriol Betamethasone
n = 5 n = 7 p-value vs. vehicle n = 4 p-value vs. vehicle p-value vs. 
calcipotriol
CD3 (number/mm2) 391.4 ± 152.1 393.7 ± 230.5 NS 134.7 ± 55.6 0.007 0.025
CD4 (number/mm2) 87.7 ± 110.7 67.6 ± 49.6 NS 5.8 ± 2.3 NS 0.016
CD8 (number/mm2) 32.9 ± 27.1 36.6 ± 42.3 NS 9.7 ± 6.6 NS NS
CD45RO (number/
mm2)
190.1 ± 191.1 172.1 ± 132.9 NS 103.3 ± 89.8 NS NS
Ki-67 (number/mm) 439.0 ± 278.0 362.8 ± 255.2 NS 147.8 ± 189.4 NS NS
CK10 (% area) 70.6 ± 21.0 73.0 ± 21.9 NS 75.7 ± 14.9 NS NS
CK16 (% area) 19.5 ± 13.5 11.9 ± 13.4 NS 7.9 ± 9.7 NS NS
Epidermal thickness 
(μm)
356.1 ± 121.4 225.9 ± 117.1 NS 98.1 ± 14.9 0.002 0.038
NS, not significant.
Immunohistochemical stainings of a keratome biopsy before (A, B and C) transplantation and after (D, E and F) transplantation  and treatment in the psoriasis xenograft SCID mouse Figure 4
Immunohistochemical stainings of a keratome biopsy before (A, B and C) transplantation and after (D, E and 
F) transplantation and treatment in the psoriasis xenograft SCID mouse. Before transplantation the expression of 
CD3 (A), CD4 (B) and CD8 (C) is seen in follicular structures and diffusely distributed in the skin. However, the intensity of 
CD4 expression is slightly decreased compared to freshly excised and fixed psoriatic skin (data not shown). Five weeks after 
transplantation including a three week treatment with vehicle the expression of CD3 (D) expression in the skin seems to be 
increased. In contrast, CD4 (E) and CD8 (F; arrows) expression is down regulated after vehicle treatment. The skin from A, B, 
C, D, E and F is from the same donor.
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therefore an excellent method for obtaining early clinical
"proof-of-concept" for comparing several treatments and
for exploring the mechanism of action of topical anti-pso-
riatic treatments in the relevant patient setting.
Conclusion
Our study demonstrates the feasibility of obtaining robust
biomarker data in the psoriasis plaque test that correlate
well with those obtained in other clinical studies. Further-
more, the biomarker data from the plaque test correlate
with biopsy data from the grafted mice.
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